to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
The mysteries of how VCs determine company value can be daunting to entrepreneurs. This uncertainty is due, in large part, to the uncertainty of the valuation process itself. From the VC Confidential blog, here is a glimpse of what that process looks like.
This brief, to-the-point VC blog entry explains why investors often consider operating cash flow as the best measure of business health. The piece also explains one way for entrepreneurs to calculate it with investors in mind.
When seeking venture capital, entrepreneurs may be asked to sign a term sheet with a no-shop clause. That means the entrepreneur agrees not to seek other investors during the final negotiations. This blog entry contains some good advice that isn't necessarily obvious to the uninitiated.
Providing management direction and Department-wide leadership and expertise in the areas of acquisition and federal assistance to ensure the timely delivery of quality goods and services that directly results in creating a more secure, democratic, and prosperous world for the benefit of the American people and the international community. Creating and implementing strategies to maximize the effectiveness, efficiency, and responsiveness of the contracting and grant making processes through Department-wide leadership in the areas of policy development, training, and support. Integrating technology, highly-experienced acquisition staff, and best business practices to offer mission-oriented and cost-effective risk management in the Department’s business areas of acquisition and federal assistance. Promoting partnerships with contractors, federal assistance recipients, and the general public by ensuring the transparency of State Department’s procurement processes while maintaining the highest level of public trust, integrity, ethical standards, and compliance with Federal and State Department procurement regulations and policies. Fostering innovation in the administration of these functions by collaborating with Department staff and the general public to explore new directions in Federal Government and Department procurement and federal assistance policies and procedures.
The Enterprise Development Network (EDN) is a strategic alliance between the Overseas Private Investment Corporation (OPIC) and the private sector. Through a growing network of private sector organizations, EDN greatly extends OPIC’s ability to provide financing and political risk insurance (PRI) to more micro-, small- and medium-sized enterprises (MSMEs) doing business in developing countries.
The structure of EDN consists of three service providers. Loan and Political Risk Insurance Originators (Originators) serve as local service providers to micro, small-medium enterprises (MSMEs) to help develop the OPIC application package, refine marketing strategies, and draft or enhance business plans. Financial institutions serve as Designated Lenders to establish OPIC-backed lending facilities that are used to make loans to MSMEs or their affiliates for projects in OPIC-eligible countries. EDN Advisers are specialists in particular business sectors and geographic areas throughout the world and assist OPIC in credit underwriting and due diligence on OPIC-funded loans.
SBA provides a number of financial assistance programs for small businesses including 7(a), 504 and disaster assistance loans.
Application forms for Finance, Insurance, and Investment
The Millennium Challenge Corporation (MCC) is a United States Government corporation designed to work with some of the poorest countries in the world.
Small biotechnology firms represent a unique national resource for economic growth that may be the fastest and most efficient mechanism to create technological innovation to convert cutting edge biomedical research into new technology breakthroughs and competitive new products. The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer(STTR) grant programs provide an opportunity for ALL key players in biomedical research to benefit. SBIR grants provide $850,000 (Phase I and II) or more and STTR grants provide $600,000 (Phase I and II) or more in research dollars to catalyze the commercialization of innovative projects that will benefit public health. Further, these grants offer company scientists an opportunity to pursue innovative projects for which company support may not be available, and they promote and foster partnerships with collaborators, including academic investigators. By serving as a collaborator, consultant, or principal investigator (for STTR), an academic investigator can gain long-term financial and scientific benefits. Collaboration with a company also offers access to company resources and expertise and possibly jobs for graduate students and postdoctoral fellows. In a rapidly changing culture where research institutions are becoming more committed to innovation and entrepreneurship to enhance the economic development of their regions, NIH SBIR and STTR grants can add value to an academic institution’s intellectual property. With rapidly expanding biological knowledge, even large corporations can develop only a limited number of promising lead ideas. Large pharmaceutical corporations often look to small biotechnology companies for the initial development of embryonic technology. Thus, the end of a successful project for a small biotechnology company is often the beginning of R&D for a large pharmaceutical corporation. NIH small business grants can help bridge the needs of both by providing early-stage funding for research that adds value to an idea, promoting partnerships that lead to a marketable product.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.